Find in Library

Prostate cancer remains an actual problem in daily practice of oncourology because of the ongoing high incidence of this pathology. The main method of treatment in patients with metastatic PC is palliative hormonal therapy. In case of disease progression and development of castration-refractory prostate cancer it is possible to provide the second line chemotherapy or hormonal therapy, as well as to treat with drugs aimed at inhibiting the so-called ligand-independent pathway of activation of androgenous receptors. The article presents an overview of the results of a recent study that evaluated the efficacy of inhibitors of insulin-like growth factor, the analogue of somatostatin - octreotide - depot.